✦ LIBER ✦

CV1 A Cost-Utility Analysis of Prophylactic Therapy for Venous Thromboembolism with Dabigatran Etexilate or Enoxaparin

✍ Scribed by Burbano-Levy, X.; Herrán, S.; Sánchez, G.; Mieth, K.; Alfonso-Cristancho, R.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prolonged enoxaparin therapy to prevent

✍ Patrick Haentjens; Katrien De Groote; Lieven Annemans 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 320 KB

Short-Term Therapy with Enoxaparin or Un

✍ Catia Argenta; Maria Angélica Pires Ferreira; Guilherme Becker Sander; Leila Bel 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 249 KB

Dabigatran versus enoxaparin for prevent

✍ R.J. Friedman; O.E. Dahl; N. Rosencher; J.A. Caprini; A.A. Kurth; C.W. Francis; 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 664 KB

PCV15 COST-EFFECTIVENESS ANALYSIS OF DAB

✍ Fernandes, RA; Quintella, FF; Teich, VD 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB

PCV12 COST-EFFECTIVENESS ANALYSIS OF DAB

✍ Fernandes, RA; Quintella, FF; Teich, VD 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

PMS38 ECONOMIC ANALYSIS OF DABIGATRAN ET

✍ Gonzalez-Rojas, N; Vieta, A; Monreal, M; Wolowacz, SE 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB